02787nam 2200637Ia 450 991027302900332120200520144314.01-280-08863-X978141757330997866100886380-8213-8372-81-4175-7330-9(CKB)1000000000031509(EBL)476228(OCoLC)727645660(SSID)ssj0000086157(PQKBManifestationID)11123674(PQKBTitleCode)TC0000086157(PQKBWorkID)10029567(PQKB)11607439(MiAaPQ)EBC476228(Au-PeEL)EBL476228(CaPaEBR)ebr10074983(CaONFJC)MIL8863(EXLCZ)99100000000003150920040928d2005 uf 0engur|n|---|||||txtccrCustoms modernization handbook[electronic resource] /edited by Luc de Wulf, José B. SokolWashington, DC World Bank20051 online resource (729 p.)Trade and development seriesDescription based upon print version of record.0-8213-5751-4 Includes bibliographical references and index.Cover; Title Page; Contents; Foreword; Acknowledgments; Abbreviations and Acronyms; Overview; PART 1 Cross-Cutting Issues; PART 2 Lessons from a Select Set of Customs Reform Initiatives; PART 3 Guidelines on Issues that Affect Customs' Operational Trade Facilitation; Index; Back CoverTrade integration contributes substantially to economic development and poverty alleviation. In recent years much progress was made to liberalize the trade regime, but customs procedures are often still complex, costly and non-transparent. This situation leads to misallocation of resources. Customs Modernization Handbook provides an overview of the key elements of a successful customs modernization strategy and draws lessons from a number of successful customs reforms as well as from customs reform projects that have been undertaken by the World Bank. It describes a number of key import procedTrade and development series.Customs administrationDeveloping countriesInternational tradeDeveloping countriesElectronic books.Customs administrationInternational trade352.4/48/091724Wulf Luc de1942-870449Sokol José B870450MiAaPQMiAaPQMiAaPQBOOK9910273029003321Customs modernization handbook2226764UNINA10597nam 22006735 450 991063771540332120240320154434.09783031150807(electronic bk.)978303115079110.1007/978-3-031-15080-7(MiAaPQ)EBC7174821(Au-PeEL)EBL7174821(CKB)25994465400041(DE-He213)978-3-031-15080-7(PPN)267811306(EXLCZ)992599446540004120230102d2022 u| 0engurcnu||||||||txtrdacontentcrdamediacrrdacarrierHandbook of Neurotoxicity /edited by Richard M. Kostrzewa2nd ed. 2022.Cham :Springer International Publishing :Imprint: Springer,2022.1 online resource (2551 pages)Includes index.Print version: Kostrzewa, Richard M. Handbook of Neurotoxicity Cham : Springer International Publishing AG,c2023 9783031150791 Cell Death Processes: Neurons and Glia -- Neuronal Necrosis -- Neuronal Apoptosis -- Autophagy Pathways -- Necrostatin Neuroprotection -- Neuronal Necroptosis, Relation to Neurological Disorders -- Multiple Cell Death Processes in Neurological Disorders -- Micorglia: Neuroprotective and Neurodestructive Propertie.s, - Selective Neurotoxins -- Survey of Selective Neurotoxinx -- RCSN Cell System for Identifying Dopaminergic Neurotoxicity -- Neurotoxicity: A complex multistage process -- Dopaminergic and Noradrenergic Neurotoxins -- Dopamine and L-dopa as Selective Endogenous Neurotoxins., Dopamine D2 Receptor Supersensitivity as a non-Degenerative Neurotoxin -- Trace Amine-Associated Receptor 1 (TAAR1) and Doapmine Receptor Sensitivity -- Dopamine Receptor Supersensitivity to Model Schizophrenia -- Pathophysiology of Obsessive-Compulsive Disorder: Insights from Normal Function and Neurotoxic Effects of Drugs, Infection, and Brain Injury -- Dopamine D3 receptors and schizophrenia / drug addiction -- Tardive Dyskinesia: Outcome of Antipsychotic Treatment and Brain Damage? -- 6-Hydroxydopamine Neurotoxicity in Adult Animal -- 6-Hydroxydopamine Neurotoxicity in Perinatal Animals -- 6-Hydroxydopa in Perinatal and Adult Animals -- MPTP Neurotoxicity Mechanisms -- Dopaminergic and Noradrenergic Neurotoxins and Neurodegenerative Disorders -- anti-NGF -- Advances in Stem Cell Research for Parkinson's Disease -- Autophagy Pathways and Parkinson's Disease -- Regulation of DA Homeostasis and Role of VMAT2 in Parkinson's Disease -- Alpha-Synuclein in Parkinson's Disease -- Dopaminergic Neurons in Parkinson's Disease -- Dopamine Oxidation and Parkinson's Disease -- Neuromelanin and Parkinson's Disease., -Iron-Induced Dopaminergic Cell Death in vivo as a Model of Parkinson's Disease -- Iron Neurotoxicity in Parkinson's Disease -- 6-Hydroxydopamine as Preclinical Model of Parkinson's Disease. - MPTP modeling of Parkinson's Disease -- MPTP: Advances from and Evergreen Neurotoxin. - MPTP and Motor Neurons -- MPTP Neurotoxicity: Actions, Mechanisms, and Animal Modeling of Parkinson's Disease -- Paraquat and Parkinson's Disease -- Rotenone Preclinical Modeling of Parkinson's Disease -- N-Methyl-(R)-Salsolinol and Parkinson's Disease -- Fusion Models and "Fusioning" in Parkinsonism: 1-Benzyl-1,2,3,4-tetrahydroisoquinoline -- Amphetamines as Neurotoxins -- METH Neurotoxicity -- Neurotoxicity of MDMA -- Cocaine influence of A2/D2 receptor heteromers -- Cocaine as a Neurotoxin -- NBOMe Neurotoxicity -- Cathinone Neurotoxicity - several chapters -- Neurotoxic Vulnerability Underlying Schizophrenia Spectrum Disorders -- Molecular Mechanism and Effects of Clostridial Neurotoxins -- Botulinum Neurotoxicity -- ~3 addl subchapters on Botulinum Neurotoxicity -- Neurotoxic Effects, Mechanisms, and Outcome of 192-IgG Saporin -- TRPV1 Activators ("Vanilloids") as Neurotoxins -- Protective Agents in Parkinson's Disease:Caffeine and Adenosine A2A Receptor Antagonists -- Physical Exercise as Intervention in Parkinsonism -- Manganese Neurotoxicity and Parkinson's Disease -- Neuroinflammation and Parkinson's Disease -- Neurotoxicity in Psychostimulant and Opiate Addiction -- Homocysteine and Cerebellar Damage -- Propionic Acid, Modeling of Autism Spectrum Disorders -- 1-Me-TIQ, and endogenous Neuroprotectant -- 5-MeO-DIPT -- 3-MD-Glutaric acid -- 3-NP and Huntington's Disease -- 25C-NBOMe -- M-30 -- Trace amine-associated receptor 1 and neuropsychiatric disorders -- PACAP as a Neuroprotectant -- Doxycycline as a Neuroprotectant -- PCP Modeling Amnesia -- Drug Abuse Neurotoxicity: Alcohol and Nicotine as Developmental Stressors -- Neurotrophic Factors and Ethanol Neurotoxicity -- Salsolinol and Addiction -- Snake Venom Toxins -- Salicylate Ototoxicity -- Serotoninergic Neurotoxins -- Nature of DSP-4-Induced Neurotoxicity -- 5,6- and 5,7-Dihydroxytryptamines as Serotoninergic Neurotoxins -- 2'NH(2)-MPTP: A Serotonin and Norepinephrine Neurotoxin -- Excitotoxins and Excitotoxicity -- Glutamate as a Neurotoxin -- Aspartate as a Neurotoxin -- Concept of Excitotoxicity via Glutamate Receptors -- Glutamate Neurotoxicity, Transport and Alternative Splicing of Transporters -- Excitotoxicity: A Complex Multistage Process Involving Different Mechanisms -- Glutamate Excitotoxicity Relation to Energy Failure -- Ionotropic Receptors in the Central Nervous System and Neurodegenerative Disorders -- Excitotoxicity and Axon Degeneration -- Glutamate Scavengers -- Quinolinate and Related Excitotoxins: Mechanisms of Neurotoxicity and Disease Relevanc -- Domoic Acid as a Neurotoxin -- BOAA and Neurotoxicit -- Endogenous Kynurenic Acid and Neurotoxicity -- Neuroprotection by Kynurenine Metabolites -- BMAA (beta-N-Methylamin -- Ionotropic Glutamate Receptors in Neurodegenerative and Other Disorders -- Okadaic acid modeling of Alzheimer's Disease -- Excitotoxicity in Parkinson's Disease -- Excitotoxicity and the Pathogenesis of Gliomas Excitotoxicity and Epielpsy; Epilepsy re Neurotoxicity Mechs -- Excitotoxicity in Multiple Sclerosis -- Excitotoxicity: Insights into Pathogenesis of AD -- Excitotoxicity and ALS: Insights into Pathogenesis -- Excitotoxicity and Amyotrophic Lateral Sclerosis -- Fungal Neurotoxins and ALS -- Excitotoxicity and Huntington Disease -- Excitotoxicity and Stroke -- Excitotoxicity in HIV Associated Neurocognitive Disordders -- Excitotoxicity and AIDS -- Excitotoxicity and Neuroprotection in Spinal Cord Injury -- Excitotoxicity in the Pathogenesis of Autism -- Cancer-Mediated Excitotoxicity., Excitotoxicity and Depression -- Lead and Excitotoxicity -- Glutamate and Neurodegeneration in the Retina -- Excitotoxicity and Epielpsy -- Seizures, Neurotrophin, Neuronal Death -- Neurodegenerative Aspets of Multiple System Atrophy -- Excitotoxicity in Ischemia and Reperfusion Injury -- Molecular, Cellular, and Behavioural Effects Produced by Perinatal Asphyxia: Neuroprotectants Targeting NMDA Receptor Signaling -- Neuroprotective Strategies in Amyotrophic Lateral Sclerosis Modulation of Neurotransmitory and Neurotrophic Input to Motor Neurons -- Neuroprotection in Demyelinating Diseases: The Therapeutic Potential of the Neurotrophins -- p75NTR: A Molecule with Multiple Functions in Amyloid-beta -- Metabolism and Neurotoxicity -- Neurotrophins and ALS -- Neurotrophic Factors & NeuroAIDS -- Neuroprotection by Poly (ADP-Ribose) Polymerase 1 (PARP-1) Inhibition -- Alzheimer's Disease and Neurotoxic Aspects -- Stem Cell Therapies for Age Associated Neurodegeneration -- Pathogenesis of Alzheimer's Disease -- Experimental Approach to Alzheimer Disease -- Potential Therapeutic Effects of Statins in Alzheimer's Disease -- Excitotoxicity and Alzheimer's Disease: Treatment Challenges -- Amyloid-beta, BDNF, and Mechanism of Neurodegeneration in Alzheimer's Diseases -- Drug Treatments: hopes, challenges -- Cannabinoids and Alzheimer's -- Heavy Metal Neurotoxicity -- Trimethyltin Neurotoxicity -- Mn Neurotoxicity -- MeHG -- Cd Neurotoxicity -- Fe Neurotoxicity -- Organoselenium -- Al Neurotoxicity -- Se Neurotoxicity -- Pb Neurotoxicity -- Cuprizone modelin of Multiple sclerosis.This handbook is a reference source for identifying, characterizing, instructing on use, and describing outcomes of neurotoxin treatments – to understand mechanisms associated with toxin use; to project outcomes of neurotoxin treatments; to gauge neurotoxins as predictors of events leading to neurodegenerative disorders and as aids to rational use of neurotoxins to model disease entities. Neuroprotection is approached in different manners including those 1) afforded by therapeutic agents – clinical and preclinical; or 2) by non-drug means, such as exercise. The amorphous term ‘neurotoxin’ is discussed in terms of the possible eventuality of a neuroprotectant producing an outcome of excess neuronal survival and a behavioral spectrum that might produce a dysfunction – akin to a neurotoxin’s effect. This new edition significantly expands on the information provided in the first edition, providing the latest research in neurotoxicity and highlighting the relationship between specific neurotoxins and the neurodegenerative disorders they can cause. It also includes new sections on the neurotoxicity of heavy metals, fungi, and snake venom. The Handbook of Neurotoxicity is thus an instructive and valuable guide towards understanding the role of neurotoxins/neurotoxicity in the expansive field of Neuroscience, and is an indispensable tool for laboratory investigators, neuroscientists, and clinical researchers.NeurophysiologyNeuronsNervous systemDiseasesToxicologyNeurochemistryCellular NeuroscienceNeurological DisordersToxicologyNeurochemistryNeurotoxicologiathubLlibres electrònicsthubNeurophysiology.Neurons.Nervous systemDiseases.Toxicology.Neurochemistry.Cellular Neuroscience.Neurological Disorders.Toxicology.Neurochemistry.Neurotoxicologia612.82Kostrzewa Richard M.MiAaPQMiAaPQMiAaPQ9910637715403321Handbook of Neurotoxicity3003072UNINA01453nam0 22003491i 450 UON0028931620231205103914.66035-253-3214-920070306d1985 |0itac50 bagerDE|||| 1||||ˆDas ‰Erlebnis und die DichtungLessing, Goethe, Novalis, HölderlinWilhelm Dilthey16. AuflGöttingenVandenhoeck & Ruprecht1985335 p.19 cm.001UON001736402001 Kleine Vandenhoeck-Reihe210 GöttingenVandenhoeck & Ruprecht.1191Goethe Johann Wolfgang VonUONC061101FIHölderlin FriedrichUONC040352FILESSING GOTTHOLD EPHRAIMUONC041083FILetteratura tedescaStoriaSec. 18.UONC061988FINOVALISUONC042719FIDEGöttingenUONL000324830.09Letteratura tedesca. Storia, descrizione, studi critici21DILTHEYWilhelmUONV13897533995Vandenhoeck & RuprechtUONV248345650ITSOL20251003RICASIBA - SISTEMA BIBLIOTECARIO DI ATENEOUONSIUON00289316SIBA - SISTEMA BIBLIOTECARIO DI ATENEOSI TED 22 II C DIL SI LO 31116 5 Erlebnis und die Dichtung89481UNIOR02837oas 2200793 a 450 991069457880332120251106213014.0(OCoLC)311142722(CONSER) 2009230359(CKB)1000000000717597(EXLCZ)99100000000071759720090227a19929999 sa aengur|||||||||||txtrdacontentcrdamediacrrdacarrierNational Hospital Ambulatory Medical Care SurveyOutpatient department summaryHyattsville, Md. U.S. Dept. of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Health Statisticsvolumes digital, PDF filesDHHS publicationAdvance data from vital and health statistics of the Centers for Disease Control and PreventionNational health statistics reports1948-383X DHHS publication ;no. (PHS)Advance data from vital and health statistics of the National Center for Health Statistics.National health statistics reports.Outpatient department summaryHospital outpatient department visitsAmbulatory medical careUtilizationUnited StatesStatisticsPeriodicalsPhysician services utilizationUnited StatesPeriodicalsMedical care surveysUnited StatesPeriodicalsAmbulatory medical careUtilizationfast(OCoLC)fst00806838Medical care surveysfast(OCoLC)fst01013897Physician services utilizationfast(OCoLC)fst01062835United Statesfasthttps://id.oclc.org/worldcat/entity/E39PBJtxgQXMWqmjMjjwXRHgrqPeriodicals.fastStatistics.fastStatistics.lcgftPeriodicals.lcgftAmbulatory medical careUtilizationPhysician services utilizationMedical care surveysAmbulatory medical careUtilization.Medical care surveys.Physician services utilization.362National Center for Health Statistics (U.S.)GPOGPODLCOCLCQGPODLCOCLCQOCLCOOCLCAOCLCFOCLCOOCLCQGILDSOCLCOOCLCQOCLCLOCLCQJOURNAL9910694578803321National Hospital Ambulatory Medical Care Survey3187076UNINA